Navigation Links
Foundation Venture Capital Group Invests in UMDNJ Company Working to Improve Leukemia Treatments

NEW BRUNSWICK, N.J., March 23 /PRNewswire/ -- Each year in the United States more than 138,000 people are diagnosed with leukemia, lymphoma or myeloma. These new cases account for 10 percent of the new total cancer cases in the U.S. per year. For several types of leukemia, the survival rate has not changed in the past 25 years.

That's why James M. Golubieski, president of Foundation Venture Capital Group, LLC, a New Jersey Health Foundation affiliate, is proud to announce that the company has made a $500,000 commitment to Actinobac Biomed Inc., a company developing a therapeutic agent targeting white leukemic blood cells for the treatment of hematological malignancies, including leukemia, myeloma and lymphoma.

"Based on current statistics, one can see there is a great need to introduce new therapies for patients suffering from hematologic malignancies," explained Dr. Scott Kachlany. "Our primary drug candidate, Leukotoxin, has shown significant success in laboratory and animal studies. With this investment from Foundation Venture Capital Group we look toward moving our research further at a more rapid pace."

Dr. Kachlany, founder of Actinobac Biomed and an associate professor of oral biology, microbiology and molecular genetics at UMDNJ-New Jersey Dental School, discovered the agent, Leukotoxin, during the course of his research at the dental school.

The research was originally funded with one-year matching grants from the New Jersey Commission on Science and Technology and the Foundation of UMDNJ Annual Program Committee Awards.

Leukotoxin is a bacterial toxin that targets while blood cells. In laboratory studies, malignant white blood cells have been determined to be more sensitive to Leukotoxin than non-cancerous white blood cells. Animal studies in Dr. Kachlany's lab using mouse models for human leukemia have shown Leukotoxin to possess significant anti-leukemia activity. The company is also looking at Leukotoxin for use in autoimmune diseases such as psoriasis, rheumatoid arthritis, multiple sclerosis, lupus, Crohn's disease and ulcerative colitis.

"While there are numerous drug candidates under development for treating various forms of leukemia, Dr. Kachlany's approach to utilizing Leukotoxin is one that we think could have significant benefits," explained George F. Heinrich, M.D., vice chair and CEO of Foundation Venture Capital Group.

Foundation Venture Capital Group was founded in 2006 to invest only in commercially viable new start-up companies developing technology at the University of Medicine & Dentistry of New Jersey. Since that time it has invested in three other UMDNJ companies including Longevica Pharmaceuticals, Inc. which is developing a chemoprotective agent that may keep normal cells healthy during cancer treatments; CellXplore, Inc., a company engaged in the development of biomarker-based in vitro diagnostic assays for cancer, initially focusing on breast cancer and Snowdon Pharmaceuticals, a drug discovery company focused on several major therapeutic areas.

For more information, contact James Golubieski, president of Foundation Venture Capital Group, at (732) 235-5400 or at

SOURCE Foundation Venture Capital Group, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Kevin McHale Instrumental in Forming the Help Me Hear Foundation
2. AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.
3. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
4. Nobel Prize Awarded to Foundation for Biomedical Research Board Member
5. The Oral Cancer Foundation Urges HPV Vaccination for Males
6. MedicAlert Foundation Joins The Alzheimers Association to Offer MedicAlert(R) + Alzheimers Association Safe Return(R) - Live 24-Hour Emergency Response for Wandering and Medical Emergencies
7. Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium
8. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
9. Five Clinical Studies to Receive $2.5 Million Under Foundations 2007 Clinical Discovery Program
10. Alpha-1 Foundation, AARC Cooperate on Study to Test 5,000 COPD Patients for Alpha-1
11. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
Post Your Comments:
(Date:11/24/2015)... , November 25, 2015 ... due to repeated failure of IVF cycles. After failure ... was totally dejected and had lost all hopes that she would be able ... Indian miracle child conceived after failure of over 15 ... abroad (UK) before they decided to take one last attempt with ...
(Date:11/24/2015)... SAN CARLOS, Calif. , Nov. 24, ... ), a leader in non-invasive genetic testing ... today announced that it will present at ... Conference in New York on Wednesday, December 2, 2015 at 1:00 p.m. ... discuss the Company,s financial results, business activities ...
(Date:11/24/2015)... /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") ... the first patient has been enrolled in ESSA,s Phase ... metastatic castration-resistant prostate cancer ("mCRPC"). the ... the United States and Canada.  ... trial, ESSA intends to demonstrate the safety, tolerability, maximum ...
Breaking Medicine Technology:
(Date:11/25/2015)... , ... November 25, 2015 , ... On November 10, ... States District Court of Connecticut on behalf of a home health care worker who ... current or former home health care workers employed by Humana, Inc., Humana at Home, ...
(Date:11/25/2015)... ... , ... On November 25, 2015, officials of Narconon Arrowhead , the ... of a new cutting edge recovery program that has been 50 years in the ... alcohol-addicted individuals with the purpose to free addicts from the symptoms and negative behaviors ...
(Date:11/25/2015)... ... , ... SCOTTSDALE, AZ) - Today, Dr. Todd C. ... and non-surgical treatments, announced the expansion of his private practice capabilities with the ... Highly trained and nationally recognized for his natural approach, Dr. Todd Hobgood serves ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Today, ... on our nation’s roadways has dropped below 10,000 for the first time since 2011. ... in 2013. , According to data released by the National Highway Traffic Safety Administration ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... of philanthropic seniors, is resulting in a way for homeless people to have ... Schaumburg have launched a new initiative whereby they are repurposing plastic bags into ...
Breaking Medicine News(10 mins):